Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Sharkey

Showing results (1-10 of 111) with videos related to

Pageof 12
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Perspectives on cancer therapy with radiolabeled monoclonal antibodiesRobert M Sharkey, David M Goldenberg
Mabs|June 19, 2019
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecanDavid M Goldenberg, Robert M Sharkey
Advanced Drug Delivery Reviews|May 30, 2008
Use of antibodies and immunoconjugates for the therapy of more accessible cancersRobert M Sharkey, David M Goldenberg
Therapeutic Delivery|July 24, 2012
Recent progress in cancer therapy with radiolabeled monoclonal antibodiesDavid M Goldenberg, Robert M Sharkey
Expert Opinion on Biological Therapy|June 2, 2012
Using antibodies to target cancer therapeuticsDavid M Goldenberg, Robert M Sharkey
Hospital Practice (1995)|October 5, 2010
Radioactive antibodies: a historical review of selective targeting and treatment of cancerDavid M Goldenberg, Robert M Sharkey
Immunotherapy|March 15, 2011
Cancer radioimmunotherapyRobert M Sharkey, David M Goldenberg
CA: a Cancer Journal for Clinicians|July 28, 2006
Targeted therapy of cancer: new prospects for antibodies and immunoconjugatesRobert M Sharkey, David M Goldenberg
Cancer Investigation|February 10, 2006
Advances in radioimmunotherapy in the age of molecular engineering and pretargetingRobert M Sharkey, David M Goldenberg
Current Opinion in Investigational Drugs (London, England : 2000)|November 28, 2008
Novel radioimmunopharmaceuticals for cancer imaging and therapyRobert M Sharkey, David M Goldenberg
Pageof 12

Showing results (1-10 of 111) with videos related to

Sort By:
Pageof 12
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Perspectives on cancer therapy with radiolabeled monoclonal antibodiesRobert M Sharkey, David M Goldenberg
Mabs|June 19, 2019
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecanDavid M Goldenberg, Robert M Sharkey
Advanced Drug Delivery Reviews|May 30, 2008
Use of antibodies and immunoconjugates for the therapy of more accessible cancersRobert M Sharkey, David M Goldenberg
Therapeutic Delivery|July 24, 2012
Recent progress in cancer therapy with radiolabeled monoclonal antibodiesDavid M Goldenberg, Robert M Sharkey
Expert Opinion on Biological Therapy|June 2, 2012
Using antibodies to target cancer therapeuticsDavid M Goldenberg, Robert M Sharkey
Hospital Practice (1995)|October 5, 2010
Radioactive antibodies: a historical review of selective targeting and treatment of cancerDavid M Goldenberg, Robert M Sharkey
Immunotherapy|March 15, 2011
Cancer radioimmunotherapyRobert M Sharkey, David M Goldenberg
CA: a Cancer Journal for Clinicians|July 28, 2006
Targeted therapy of cancer: new prospects for antibodies and immunoconjugatesRobert M Sharkey, David M Goldenberg
Cancer Investigation|February 10, 2006
Advances in radioimmunotherapy in the age of molecular engineering and pretargetingRobert M Sharkey, David M Goldenberg
Current Opinion in Investigational Drugs (London, England : 2000)|November 28, 2008
Novel radioimmunopharmaceuticals for cancer imaging and therapyRobert M Sharkey, David M Goldenberg
Pageof 12